Oral fluoropyrimidine-induced severe hyperlipidemia

Creative Commons License

YILDIZ B., Kavgaci H., Fidan E., GUNGOR E., ERSOZ H. O., ÖZDEMİR F., ...More

ASIAN BIOMEDICINE, vol.4, no.4, pp.627-630, 2010 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 4
  • Publication Date: 2010
  • Doi Number: 10.2478/abm-2010-0079
  • Journal Name: ASIAN BIOMEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.627-630
  • Keywords: Adverse event, capecitabine, hypertriglyceridemia, oral fluoropyrimidine, UFT (R) drug, METASTATIC COLORECTAL-CANCER, HYPERTRIGLYCERIDEMIA, FLUOROURACIL, LEUCOVORIN
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background: Severe hyperlipidemia secondary to capecitabine, an oral fluoropyrimidine, is a very rare condition. There are no reported cases of hyperlipidemia associated with Uracil/tegafur (U FT).